Table 3 Baseline BMD and change in BMD with 12-month tamoxifen therapy

From: Lack of association between oestrogen receptor polymorphisms and change in bone mineral density with tamoxifen therapy

Time point

All patients

Premenopausal

Postmenopausal

Previous chemotherapy

No chemotherapy

Lumbar spine

 Baseline (g cm−2)

1.14 (1.12 to 1.16)

1.17 (1.14 to 1.21)a

1.13 (1.10 to 1.15)a

1.14 (1.11 to 1.16)

1.15 (1.12 to 1.18)

 

n=262

n=91

n=171

n=123

n=139

 % Change at 12 months after tamoxifen

−0.9 (−1.6 to −0.2)

−2.4 (−3.6 to −1.2)b

−0.1 (−1.0 to 0.7)b

+0.5 (−0.5 to 1.5)d

−2.2 (−3.2 to−1.3)d

 

n=218

n=77

n=141

n=105

n=113

Hip

 Baseline (g cm−2)

0.99 (0.97 to 1.01)

1.00 (0.97 to 1.03)

0.98 (0.96 to 1.01)

0.98 (0.96 to 1.00)

1.00 (0.97 to 1.02)

 

n=256

n=90

n=166

n=120

n=136

 % Change at 12 months after tamoxifen

0.4 (−0.3 to 1.0)

−0.5 (−1.5 to 0.6)c

+0.9 (0.0 to 1.7)c

+1.3 (0.4 to 2.2)e

−0.5 (−1.5 to 0.4)e

 

n=211

n=78

n=133

n=103

n=108

  1. Abbreviation: BMD=bone mineral density.
  2. For baseline DXA measurements, the 95% confidence interval of mean BMD is given for all patients in each subgroup. For percentage change at 12 months, 95% confidence interval of mean percentage change is given for those patients in each subgroup with both baseline and 12-month measurements.
  3. P-values signify comparisons between two means with the same letter.
  4. aP=0.032.
  5. b,d,eP<0.01.
  6. cP=0.065.